Rubella Therapeutic Pipeline Review H2 2014 Report at ReportsnReports.com

Share Article

ReportsnReports.com adds “Rubella – Pipeline Review, H2 2014” to its store. The report provides an overview of the Rubella therapeutic pipeline.

Rubella Therapeutic Pipeline Review

Rubella Therapeutic Pipeline Review

The report "Rubella Pipeline Review, H2 2014" provides comprehensive information on the therapeutic development for Rubella. Rubella is an illness that primarily affects the skin and lymph nodes. It is caused by the rubella virus which is typically transmitted by droplets from the nose or throat that others breathe in. Rubella is a significant health risk for pregnant women. But many children have such placid symptoms that they're unconscious of being infected. Most rubella infections today appear in young, non-immunized adults rather than in kids. Complete Report is Available @ http://www.reportsnreports.com/reports/321911-rubella-pipeline-review-h2-2014.html .

It also reviews key players involved in the therapeutic development for Rubella and special features on late-stage and discontinued projects. Companies discussed in this Rubella Pipeline Review H2 2014 report include Beijing Tiantan Biological Products Co., Ltd., Biological E. Limited China National Pharmaceutical Group Corporation, GlaxoSmithKline plc, Prometheon Pharma, LLC, Sinovac Biotech Ltd., Universal Stabilization Technologies, Inc.

Drugs profile discussed in this Rubella Pipeline Review H2 2014 report include Cell Therapy for Measles, Mumps and Rubella, varicella vaccine, rubella vaccine, measles rubella vaccine. Order a Purchase copy of this report @ http://www.reportsnreports.com/Purchase.aspx?name=321911 .

Table of Contents

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Rubella Overview 6
Therapeutics Development 7
Pipeline Products for Rubella - Overview 7
Pipeline Products for Rubella - Comparative Analysis 8
Rubella - Therapeutics under Development by Companies 9
Rubella - Therapeutics under Investigation by Universities/Institutes 11
Rubella - Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Unknown Stage Products 15
Rubella - Products under Development by Companies 16
Rubella - Products under Investigation by Universities/Institutes 17
Rubella - Companies Involved in Therapeutics Development 18
Rubella - Therapeutics Assessment 26
Drug Profiles 32
Cell Therapy for Measles, Mumps and Rubella - Drug Profile 32
measles + mumps + rubella + varicella vaccine - Drug Profile 33
measles + mumps + rubella + varicella vaccine - Drug Profile 34
measles + mumps + rubella vaccine - Drug Profile 35
measles + mumps + rubella vaccine - Drug Profile 36
measles + mumps + rubella vaccine - Drug Profile 37
measles + rubella vaccine - Drug Profile 38
measles + rubella vaccine - Drug Profile 39
measles + rubella vaccine - Drug Profile 40
rubella vaccine - Drug Profile 41
Rubella - Recent Pipeline Updates 42
Rubella - Dormant Projects 43
Appendix 44

List of Tables
Number of Products under Development for Rubella, H2 2014 7
Number of Products under Development for Rubella - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 10
Number of Products under Investigation by Universities/Institutes, H2 2014 11
Comparative Analysis by Late Stage Development, H2 2014 12
Comparative Analysis by Clinical Stage Development, H2 2014 13
Comparative Analysis by Early Stage Development, H2 2014 14
Comparative Analysis by Unknown Stage Development, H2 2014 15
Products under Development by Companies, H2 2014 16
Products under Investigation by Universities/Institutes, H2 2014 17
Rubella - Pipeline by Beijing Tiantan Biological Products Co., Ltd., H2 2014 18
Rubella - Pipeline by Biological E. Limited, H2 2014 19
Rubella - Pipeline by China National Pharmaceutical Group Corporation, H2 2014 20
Rubella - Pipeline by GlaxoSmithKline plc, H2 2014 21
Rubella - Pipeline by Prometheon Pharma, LLC, H2 2014 22
Rubella - Pipeline by Sinovac Biotech Ltd., H2 2014 23
Rubella - Pipeline by Universal Stabilization Technologies, Inc., H2 2014 24
Rubella - Pipeline by Zydus Cadila Healthcare Limited, H2 2014 25
Assessment by Monotherapy Products, H2 2014 26
Assessment by Combination Products, H2 2014 27
Number of Products by Stage and Route of Administration, H2 2014 29
Number of Products by Stage and Molecule Type, H2 2014 31
Rubella Therapeutics - Recent Pipeline Updates, H2 2014 42
Rubella - Dormant Projects, H2 2014 43

List of Figures
Number of Products under Development for Rubella, H2 2014 7
Number of Products under Development for Rubella - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Comparative Analysis by Clinical Stage Development, H2 2014 13
Comparative Analysis by Early Stage Products, H2 2014 14
Assessment by Monotherapy Products, H2 2014 26
Assessment by Combination Products, H2 2014 27
Number of Products by Top 10 Routes of Administration, H2 2014 28

Explore more reports on Pharmaceuticals industry at http://www.reportsnreports.com/market-research/pharmaceuticals/ .

About Us:
ReportsnReports.com is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Ritesh Tiwari
ReportsnReports
+1 (888) 391-5441
Email >
@LifeSciReports
Follow >
Sandler Research
since: 04/2014
Like >
Follow us on
Visit website